The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy.
about
Optimization of cardiac metabolism in heart failureTargeting myocardial substrate metabolism in heart failure: potential for new therapiesHyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathwaysRole of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heartGLP-1 (7-36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles.Metabolomic analysis of pressure-overloaded and infarcted mouse hearts.GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.Cardiovascular and hemodynamic effects of glucagon-like peptide-1.Myocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function.Improved diabetic control in advanced heart failure patients treated with left ventricular assist devicesGlucose phosphorylation is required for insulin-dependent mTOR signalling in the heart.Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathyModulating fatty acid oxidation in heart failure.Chronic heart failure selectively induces regional heterogeneity of insulin-responsive glucose transporters.Adrenergic activation, fuel substrate availability, and insulin resistance in patients with congestive heart failureResveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium.Metabolic energetics and genetics in the heart.Direct Evidence that Myocardial Insulin Resistance following Myocardial Ischemia Contributes to Post-Ischemic Heart FailureHyperpolarized (13)C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart.Emerging drugs for acute and chronic heart failure: current and future developments.Animal models of insulin resistance and heart failure.A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus.Metabolic modulation and cellular therapy of cardiac dysfunction and failure.Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.β-Adrenergic Receptor and Insulin Resistance in the Heart.Relation of regional fat distribution to left ventricular structure and function.Potential of metabolic agents as adjunct therapies in heart failure.Rethinking Heart Failure.Metabolic remodelling in human heart failure.Cardiovascular effects of incretin-based therapies.The potential role of sphingolipid-mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure.Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes.Cardiogenic diabetes.Heart failure and loss of metabolic controlEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Mitochondrial dysfunction and its impact on diabetic heart.Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.Metabolic remodelling in hypertrophied and failing myocardium: a review.Macrophage ubiquitin-specific protease 2 modifies insulin sensitivity in obese mice.Metformin prevents the development of chronic heart failure in the SHHF rat model.
P2860
Q27023021-03EDF97D-AA6F-4728-9A5B-76A046B37CD1Q27694733-0195631A-2F05-4A5C-8019-204029067120Q28565051-B9F018FF-A87A-461E-BD61-3D330965D60EQ28568921-09CAF462-4C4D-4189-A071-50B625A433B0Q30411123-BE05EDFE-928D-4618-9374-22F7D31754B6Q33916918-F6D60E5F-E11D-46C8-90ED-EB22825F6F49Q33917887-C1F503E3-98FD-438A-91CE-5E829D34D83EQ33993725-BFB88763-4B54-4275-BBE1-5A1F23E38877Q34426167-25CA5F05-B420-4C0C-B009-5602DD47B62FQ34514408-F110E94F-CFF8-49E6-81F2-6780453F2CEDQ34635114-1EEEA4E3-FDB4-4A32-AF03-63AA46CE6E9DQ34786386-4B081189-4296-4B0C-9C7E-D70EA76CF75CQ34808505-36057488-BE0A-4D51-B6C3-AA5AC5B65564Q35543414-D0DC5C2A-ECCC-4EFD-8456-BB9CD50577E0Q35831382-54F56E19-AC8F-4492-B252-E5DAE2583BACQ35886665-8AB57202-DCDF-4E70-850C-90105FA445E9Q36225161-D0A1C633-2B6B-4569-8590-86C43888027AQ36367130-1A32D66F-32C7-4E82-9B1F-9E7159D2B071Q36540577-15729D95-CDD1-4B78-9827-9E6A1AACBDDDQ36758585-6ED3B4DC-3742-4C91-B713-6109D438C6F4Q36944915-9C3E3D15-9C7B-46FB-BB49-794EEC9457ADQ37031357-899D466B-97AC-43FF-A6FA-4E1D78F33AE1Q37296154-F89F1089-ADFF-4A97-A78D-88EF1B863F68Q37322877-46EC22DF-8EBD-49F6-9F85-545E494F8E02Q37551918-3FEA5B6E-75E5-4C83-B024-898C873CC694Q37597280-C2A5D8C3-59DC-49BD-B928-3AE100B43434Q37608595-EB434B24-BB20-45FD-823B-28D3B0EB1305Q37711505-017E02AC-0080-479A-B0F2-6D7F3DBE265FQ37849446-8238EC10-E3B6-43A8-B954-0511006DC78DQ37977336-F6D89AA3-5C14-49CC-8083-2F5180FCCC04Q38023943-0C18875A-1CAA-4757-9FDB-3BCA69F77C4CQ38129182-092D72C0-A3EE-4A56-967D-500DC87EBE07Q38156709-240FCE09-8B88-4093-BB6C-68B0973324B7Q38171215-4B3667EE-0D8B-4BF5-A167-41E169C3FB76Q38389314-A35B1E3F-5F79-49B3-B97A-57A098CD0B81Q38946122-377C9DC0-BB25-4862-9F7B-F5C954C8FEC7Q39360754-C9AEF1C1-DD94-41E2-AB59-D8E0D986164EQ39395331-2FB53A27-5D30-49AF-89BF-88E2DFED124AQ41682336-40045357-E6E9-4B54-AF72-C31F1FA6024BQ41885618-E7A11684-E87C-43B0-82B8-D67C3BD83B2A
P2860
The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The development of myocardial ...... vanced dilated cardiomyopathy.
@en
The development of myocardial ...... vanced dilated cardiomyopathy.
@nl
type
label
The development of myocardial ...... vanced dilated cardiomyopathy.
@en
The development of myocardial ...... vanced dilated cardiomyopathy.
@nl
prefLabel
The development of myocardial ...... vanced dilated cardiomyopathy.
@en
The development of myocardial ...... vanced dilated cardiomyopathy.
@nl
P2093
P1476
The development of myocardial ...... vanced dilated cardiomyopathy.
@en
P2093
Anthony Sturzu
Carol Stolarski
Dariush Elahi
Lazaros A Nikolaidis
Richard P Shannon
You-Tang Shen
P304
P356
10.1016/J.CARDIORES.2003.11.027
P577
2004-02-01T00:00:00Z